The Claim

In patients with advanced non-small cell lung cancer, daily oral supplementation with 510 mg eicosapentaenoic acid and 200 mg docosahexaenoic acid for six weeks is associated with a statistically significant reduction in plasma levels of C-reactive protein and interleukin-6, but not tumor necrosis factor-alpha or prostaglandin E2.

Source: Effect of omega 3 fatty acids on C-reactive protein and interleukin-6 in patients with advanced nonsmall cell lung cancer

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
41score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In patients with advanced non-small cell lung cancer, taking 510 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid daily for six weeks lowers plasma levels of C-reactive protein and interleukin-6, but does not change levels of tumor necrosis factor-alpha or prostaglandin E2.

See the scientific wording

In patients with advanced non-small cell lung cancer, daily oral supplementation with 510 mg eicosapentaenoic acid and 200 mg docosahexaenoic acid for six weeks is associated with a statistically significant reduction in plasma levels of C-reactive protein and interleukin-6, but not tumor necrosis factor-alpha or prostaglandin E2, suggesting a selective anti-inflammatory effect on specific biomarkers in this population.

Why this might work

EPA and DHA from fish oil enter immune and liver cells, replace other fats in cell membranes, and block signals that turn on inflammation genes. This stops the production of IL-6, which in turn stops the liver from making CRP. Other inflammatory molecules like TNF-alpha and PGE2 are not affected because they use different pathways that omega-3s do not block.

Supported mechanismbased on 1 study

What the research says

1 study
  1. Study: Effect of omega 3 fatty acids on C-reactive protein and interleukin-6 in patients with advanced nonsmall cell lung cancer

    In people with advanced lung cancer, taking a specific fish oil supplement for six weeks lowered two inflammation markers (CRP and IL-6) but didn’t change two others (TNF-alpha and PGE2), just like the claim said.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.